Oligonucleotide Synthesis – Speed up your Process
Aug 07 2023
The demand for the production of oligonucleotides is growing rapidly. Oligos are produced using solid-phase synthesis that offers an elevated yield of purified product. In order to be used in downstream applications, they must be cleaved from the solid support and the protecting groups removed. Nowadays, the synthesis process is automated while the post-processing, cleavage and deprotection (C&D) plus evaporation steps are still carried out manually. This creates a bottleneck in the process affecting productivity and efficiency.
In an era where optimising time and resources is paramount, Analytix is thrilled to introduce the Milestone wavePREP that provides C&D plus removes the evaporation stage in a single step in under 90 minutes saving up to 95% of the processing time. The system can be used with up to 6 deep well plates, multiple small columns, or larger columns up to 700ml. The process uses a gas phase method and all reaction conditions are accurately controlled to maximise the quality and yield.
Tedious manual processes are replaced with seamless, automated actions so the laboratory workflow becomes more efficient. Most of the steps are automated and software controlled such as the lowering of the well plates or columns into the reactor, reagent addition, draining and venting. The automatic loading and unloading of reagents ensures there is no operator exposure to chemicals such as ammonia. Early adopters of wavePREP have reported remarkable results with reduction in processing time coupled with excellent C&D yields even with tricky protection groups and linkers whilst eliminating cross contamination.
More information online
Buyers Guide - Major producers of analytical equipment who wish to introduce and sell their products to buyers in science and industry - Over 1,000 products and services that these companys man...
View all digital editions
Jan 17 2024 Birmingham, UK
Jan 24 2024 Tokyo, Japan
Jan 29 2024 Dubai, UAE
Jan 31 2024 Tokyo, Japan
Feb 03 2024 Boston, MA, USA